WithdrawnPhase 3NCT07492875

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Studying Adult acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
ImmunityBio, Inc.
Principal Investigator
Jayson Garmizo
ImmunityBio, Inc.
Intervention
Nogapendekin alfa inbakicept (NAI)(biological)
Enrollment
10 target
Eligibility
18-105 years · All sexes
Timeline
20262029

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07492875 on ClinicalTrials.gov

Other trials for Adult acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Adult acute respiratory distress syndrome

← Back to all trials